Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies

1 Jan 2014

Abstract excerpt

In Alzheimer's disease, progressive supranuclear palsy, and a number of other neurodegenerative diseases, the microtubule associated protein tau aggregates to form intracellular neurofibrillary tangles and glial tangles, abnormal structures that are part of disease pathogenesis. Disorders with aggregated tau are called tauopathies. Presently, there are no disease-modifying treatments for this disease class. Tau...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Trace Elements in Health
Share to Alzheimer's disease research and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25072694
DOI: 10.1038/mtna.2014.30

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For TauopathiesPMID 25072694Read ↗

Evaluating the efficacy of commercially available antisense oligonucleotides to reduce mouse and human tau <i>in vivo</i>Semantic proximity Read ↗

MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model.Semantic proximity Read ↗

Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Semantic proximity Read ↗

<i>MAPT</i> Splicing Modulators as a Therapeutic Strategy for TauopathiesSemantic proximity Read ↗

Bottom-up design of small molecules that stimulate exon 10 skipping in mutant MAPT pre-mRNA.Semantic proximity Read ↗

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trialSemantic proximity Read ↗

Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.Semantic proximity Read ↗

AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer’s diseaseSemantic proximity Read ↗

The MIR-NAT <i>MAPT-AS1</i> does not regulate Tau expression in human neuronsSemantic proximity Read ↗

Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative DiseasesSemantic proximity Read ↗

Antisense Reduction of Tau in Adult Mice Protects against SeizuresSemantic proximity Read ↗

Tau Silencing by siRNA in the P301S Mouse Model of TauopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.